ATE517098T1 - Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren - Google Patents

Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren

Info

Publication number
ATE517098T1
ATE517098T1 AT05717377T AT05717377T ATE517098T1 AT E517098 T1 ATE517098 T1 AT E517098T1 AT 05717377 T AT05717377 T AT 05717377T AT 05717377 T AT05717377 T AT 05717377T AT E517098 T1 ATE517098 T1 AT E517098T1
Authority
AT
Austria
Prior art keywords
beta
amyloid inhibitors
acylaminothiazole derivatives
acylaminothiazole
derivatives
Prior art date
Application number
AT05717377T
Other languages
English (en)
Inventor
Sylvie Baltzer
Marc Pascal
Dorsselaer Viviane Van
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0400388A external-priority patent/FR2865207B1/fr
Priority claimed from FR0408116A external-priority patent/FR2873374B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of ATE517098T1 publication Critical patent/ATE517098T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT05717377T 2004-01-16 2005-01-07 Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren ATE517098T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0400388A FR2865207B1 (fr) 2004-01-16 2004-01-16 Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR0408116A FR2873374B1 (fr) 2004-07-22 2004-07-22 Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
PCT/FR2005/000029 WO2005073202A1 (fr) 2004-01-16 2005-01-07 Derives d’acylaminothiazole et leur application comme inhibiteurs de beta-amyloide

Publications (1)

Publication Number Publication Date
ATE517098T1 true ATE517098T1 (de) 2011-08-15

Family

ID=34828646

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05717377T ATE517098T1 (de) 2004-01-16 2005-01-07 Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren

Country Status (11)

Country Link
US (2) US7371770B2 (de)
EP (1) EP1709018B1 (de)
JP (1) JP4813371B2 (de)
AR (1) AR047383A1 (de)
AT (1) ATE517098T1 (de)
DK (1) DK1709018T3 (de)
IL (1) IL176772A0 (de)
PT (1) PT1709018E (de)
SI (1) SI1709018T1 (de)
TW (1) TWI350287B (de)
WO (1) WO2005073202A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005209442B2 (en) * 2004-01-16 2011-03-31 Sanofi-Aventis Acylaminothiazole derivatives, preparation method thereof and use of same in therapeutics
PT1709018E (pt) * 2004-01-16 2011-10-24 Sanofi Sa Derivados de acilaminotiazole e sua aplicação como inibidores
JP2007119416A (ja) 2005-10-31 2007-05-17 Bayer Cropscience Ag 殺虫性２−アシルアミノチアゾール−４−カルボキサミド類
WO2007084391A2 (en) * 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
WO2007116106A1 (es) * 2006-04-12 2007-10-18 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
EP2173728A2 (de) 2007-07-17 2010-04-14 Amgen Inc. Heterocyclische pkb-modulatoren
TW200922564A (en) * 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2010012793A1 (en) * 2008-08-01 2010-02-04 Bayer Cropscience Sa Fungicide aminothiazole derivatives
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
KR101095630B1 (ko) 2009-06-17 2011-12-19 주식회사 이노파마스크린 베타 아밀로이드 펩타이드와 ｖｅｇｆ의 상호작용을 억제하는 물질을 탐색 방법 및 그에 의해서 탐색된 저해제
EP2273273A1 (de) 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibitoren der Nitrierung von Amyloid-ß-Peptiden und ihre Verwendung bei der Diagnose und Behandlung von Morbus Alzheimer
EP2492269A4 (de) * 2009-10-19 2013-08-07 Taisho Pharmaceutical Co Ltd Aminothiazolderivat

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024392A1 (en) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
JP2006504796A (ja) * 2002-10-09 2006-02-09 ファイザー・プロダクツ・インク 神経変性性障害を処置するためのチアゾール化合物
PT1709018E (pt) * 2004-01-16 2011-10-24 Sanofi Sa Derivados de acilaminotiazole e sua aplicação como inibidores

Also Published As

Publication number Publication date
TWI350287B (en) 2011-10-11
JP4813371B2 (ja) 2011-11-09
US20080176911A1 (en) 2008-07-24
US7371770B2 (en) 2008-05-13
US20060293366A1 (en) 2006-12-28
EP1709018B1 (de) 2011-07-20
WO2005073202A1 (fr) 2005-08-11
PT1709018E (pt) 2011-10-24
AR047383A1 (es) 2006-01-18
IL176772A0 (en) 2006-10-31
EP1709018A1 (de) 2006-10-11
US7759377B2 (en) 2010-07-20
TW200533659A (en) 2005-10-16
SI1709018T1 (sl) 2011-11-30
DK1709018T3 (da) 2011-11-14
JP2007520478A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
ATE472546T1 (de) 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
DE602005015699D1 (de) Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
DE602004021037D1 (de) Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren
ATE444068T1 (de) Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
ATE378338T1 (de) Pyrrolopyridinderivate und deren verwendung als crth2-antagonisten
ATE463482T1 (de) Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
ATE419849T1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
DE602005022115D1 (de) Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
ATE435859T1 (de) Gyraseinhibitoren und deren verwendungen
MA29039B1 (fr) Dibenzylamines et derives
ATE501159T1 (de) 1-(d-glykopyranosyl)-3-(4- cyclopropylphenylmethyl)-4-halogenindolderivate und deren verwendung als sglt-inhibitoren
ATE426597T1 (de) Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
EP1746902A4 (de) Multilektin-affiniätschromatografie und verwendung dafür
ATE471938T1 (de) Substituierte diazaspiroä4.5üdecanderivate und deren verwendung als neurokininantagonisten
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
ATE517098T1 (de) Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
ATE382040T1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren
DE602005020158D1 (de) Glucanderivate und herstellungsverfahren dafür
ATE396185T1 (de) Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
DE602005009988D1 (de) Härtbare Zusammensetzung und deren Verwendung
DE60311598D1 (de) Naphthyridin-derivate und ihre verwendung als fungizide
ATE442366T1 (de) Oxazolidinonderivate und ihre verwendung als antibiotika
DE602006004713D1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1709018

Country of ref document: EP